Real-world Utilization Of An Implantable Pulmonary Artery Pressure Sensor In Female Patients: Insights From The HF2Registry.

Women have been underrepresented in heart failure (HF) trials, including key trials for implantable pulmonary artery pressure (PAP) sensors. Sex-specific analysis of the use of ambulatory hemodynamic monitoring devices are lacking. Hemodynamic Frontiers in Heart Failure (HF²) is an academic consortium of 14 US centers that has developed a registry to collect data on patients following PAP sensor implantation. We analyzed patients with at least 12 months of hemodynamic monitoring data and compared patients based on reported sex. Clinical events including ED visits, HF hospitalizations, and death have been captured. Baseline demographic and implant hemodynamic data were compared using independent samples t-test (IBM SPSS Statistics Version 29.0). The registry has IRB approval from individual sites and is supported by CTSA Award UL1TR002366. Of 238 patients, 100 (42%) were female. Women were more likely to have lower creatinine, higher BMI and ejection fraction (Table 1). They were less likely to have ischemic etiology or baseline SGLT2 inhibitor use. There were no significant differences in baseline hemodynamics. Female patients had fewer total events than their male counterparts (1.49 vs 1.91 events/person-year) and fewer HF hospitalizations (Figure 1). The majority of ED visits were non-cardiac and the majority of hospitalizations were not HF-related. There were 5 deaths total: 3 HF-related in males, 1 HF-related in a female and 1 non-cardiac in a female. Four patients progressed to LVAD, 3 of which were males. Three patients progressed to ESRD, all males. The HF² Registry is a real-world, multi-center registry of an approved PAP sensor. As compared to key trials leading to initial and expanded indications for the devices, this registry houses a higher proportion of female patients. Although there were no differences in baseline hemodynamics, there were substantial sex-based variations in other demographics and in outcomes. More research is needed to understand potential sex-specific effects and to encourage higher female representation in HF device trials and utilization. [ABSTRACT FROM AUTHOR]